GlassScriptPhysician profile
Edith Ruchelle Steele
NPI 1225466758
$3,344.13
in general payments reported to CMS, 2019-2025
36 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $632 · 2023: $971 · 2024: $854 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $704.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $479.86 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $316.19 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Corcept Therapeutics | $243.58 | 2021-2024 | Korlym |
| Amgen INC. | $156.75 | 2022-2025 | Repatha, Krystexxa, Otezla |
| Sumitomo Pharma America, INC. | $156.28 | 2023-2025 | Gemtesa |
| Abbvie INC. | $136.98 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $99.02 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $81.37 | 2023-2025 | Ingrezza |
| Pfizer INC. | $75.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $72.22 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $67.02 | 2024-2025 | Voquezna |
| Insulet Corporation | $58.64 | 2023 | Omnipod |
| Nevro Corp. | $52.77 | 2022-2023 | Senza |
| Abbott Laboratories | $51.00 | 2022-2024 | Proclaim |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.32 | 2022-2023 | |
| Exact Sciences Corporation | $46.18 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $44.76 | 2022-2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $41.19 | 2024 | Inspire |
| Tempus Ai, INC | $41.08 | 2024 | |
| Antares Pharma, INC. | $40.96 | 2024-2025 | Xyosted |
| Inogen, INC. | $36.37 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Phadia US INC. | $34.56 | 2021-2023 | Immunocap |
| Averitas Pharma INC. | $34.54 | 2025 | Qutenza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.19 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $24.50 | 2022 | |
| Optos, INC. | $23.97 | 2021 | |
| Edwards Lifesciences Corporation | $20.76 | 2025 | |
| Merck Sharp & Dohme LLC | $20.48 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $17.25 | 2021 | |
| Axsome Therapeutics, INC. | $15.88 | 2025 | Auvelity |
| Abiomed | $15.80 | 2022 | |
| Dexcom, INC. | $15.72 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $13.13 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.79 | 2022 | |
| Alexion Pharmaceuticals, INC. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edith Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.